Assistant Professor, PhD, Cancer researcher, Cell Biologist @IcahnMountSinai. Passionate about Science and Photography, Views are my own
New York
Joined July 2019
- Tweets856
- Following745
- Followers615
- Likes2.9K
Pinned Tweet
Thrilled to share our latest publication on castration resistance published in @CellReports
cell.com/cell-reports/fullte…
Key Discoveries
BCL2 a driver of early castration resistance.
Crosstalk in AR-BCL2-PI3K signaling pathways.
Venetoclax + ENZ combo delated CSPC growth.
Goutam Chakraborty retweeted
In the news from China and Peking University👇
Cell publisher investigates editor accused of soliciting bribes from China
Probe triggered by social media post in which prominent biologist singled out Chinese-born editor-in-chief of medical journal Cancer Cell
scmp.com/news/china/science/…
Congratulations to Postdoctoral Fellow Prathiksha Prabhakaraalva to present her research at NYC NCI postdoc Scientific Symposium #chakrabortylab @TischCancer @MountsinaiUro @IcahnMountSinai #prostatecancer
Thank you @soulehoward1 for your support to early career investigators like us and for your leadership @PCF_Science @PCFnews
Goutam Chakraborty retweeted
Prostate cancer displaying cells w/histologically visible neuroendocrine granules (so-called 'Paneth cell-like', though lack lysozyme & +NE markers unlike GI cells) - important to differentiate from small cell/high-grade NE carcinoma - can be seen in any grade of PCa
Thrilled to be appointed as the #AssociatedDirector , Shared Resources, at NCI designated Tisch Cancer Center at Icahn School of Medicine at Mount Sinai. A new chapter in my #academicjourney. @TischCancer @IcahnMountSinai @MountsinaiUro #research #cancercellbiologists
Goutam Chakraborty retweeted
NIH Director Jay Bhattacharya, a former colleague of Harvard President Alan Garber, refused a directive from Trump on Friday to cut Harvard’s federal research grants, Politico reported Saturday.
@HugoChiassonn and @EliseSpenner report.
thecrimson.com/article/2026/…
Goutam Chakraborty retweeted
Transformative opportunity for early career faculty @hhmi_science #FreemanHrabowski Scholars competition opens 11/3/2026 but you can get started NOW: view application components, establish eligibility, and unlock example applications and other resources hhmi.org/programs/freeman-hr…
Goutam Chakraborty retweeted
The Maitra Lab @nyulangone @Perlmutter_CC is recruiting for a research scientist, with immediate availability. Please see the announcement below.
We are excited to grow our #PancreaticCancer research team as we approach the one year mark in NYC!
Goutam Chakraborty retweeted
🚨We're growing! Our lab at @TischCancer is #recruiting postdocs for 3 fully funded NIH projects. If you want to explore the biology of tumor dormancy, join us!!! Projects focus on:🧠Cancer neuroscience, ECM-driven dormancy, HER2 biology.
📩 email for more info or send your CV👇
Goutam Chakraborty retweeted
🧬 We're Hiring: Postdoctoral Fellow – Computational Biology & Machine Learning
The Shrestha Lab at the @CPDR_Labs, Bethesda, MD is looking for motivated Postdocs to join our team
📌 More Details: iaaxmg.fa.ocs.oraclegovcloud…
#Hiring #Postdoc #ComputationalBiology #MachineLearning
Goutam Chakraborty retweeted
We are recruiting a postdoc to work on an NIH funded project to determine the role of aging and oncogene-induced stromal senescence on prostate cancer initiation and therapy resistance. See job posting and recent publication below.
ummsjobs.com/job/11591/
aacrjournals.org/cancerdisco…
Goutam Chakraborty retweeted
✨ New Year, New Lab, New Beginnings ✨ Join us in New York as we are building our team. We are interested in understanding the molecular and cellular mechanisms underlying human breast development, tissue homeostasis, and breast cancer. sahulab.com Please RT.
Goutam Chakraborty retweeted
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
Goutam Chakraborty retweeted
Absolutely practice changing!! One of the most stunning developments in the treatment of patients with metastatic pancreatic cancer !! It is one of the rare moments in oncology which you will always remember ! Like the imatinib, trastuzumab presentations @ASCO #ASCO26 @OncoAlert
Laboratory Visit of Dr. Richard Izquierdo Health & Science Charter School AP bio high sc student at #chakrabortlab @IcahnMountSinai @MountsinaiUro @TischCancer #stem . Discussing our reaseach with high school student to inspire them for their career goal. – at Manhattan, NY
Goutam Chakraborty retweeted
Cancer survival in the U.S. just crossed 70%.
It was 63% in the 1990s.
That gap = 4.8M people alive today.
This one chart captures survival gains across 29 cancer types.
The wins are real.
So is the unfinished work.
▪️CML: 31% → 72%
▪️Multiple myeloma: 32% → 62%
▫️Kidney: 59% → 82%
▫️Metastatic melanoma: 16% → 35%
▫️Childhood ALL: 80% → 92%
But some cancers barely moved.
Cervical cancer outcomes actually worsened.
None of this is abstract progress, though.
These are birthdays, grandkids, and years of life returned.
This is what funded science does.
Next time someone asks if cancer research works, show them this (full) chart.
- - - - -
Source: ACS Cancer Statistics 2026 · SEER · 𝘷𝘪𝘢 @Jori_health
- - - - -
